Pioglitazone

Pioglitazone (CAS 111025-46-8) is an oral antidiabetic active pharmaceutical ingredient belonging to the thiazolidinedione class. It functions as an insulin sensitizer, targeting peripheral tissue resistance in the management of type 2 diabetes mellitus.

Pharmaceutical manufacturers source it as a finished API for solid dosage form development. Pioglitazone is the active ingredient in tablet formulations for type 2 diabetes, where it reduces insulin resistance in muscle and adipose tissue.

It works without stimulating pancreatic insulin secretion. Generic drug manufacturers use it as the primary API in both monotherapy and fixed-dose combination tablets alongside metformin or glimepiride for patient care.

Pharmaceutical intermediates suppliers also supply it to support synthesis research and formulation development pipelines targeting metabolic disease indications. This supports the growth of the global pharmaceutical market.

Contract development and manufacturing organizations (CDMOs) source it for bioequivalence study batches and commercial-scale tablet production. Pioglitazone is supplied as a white to off-white crystalline powder for industrial use.

It is available in pharmaceutical-grade specifications, including USP and Ph.Eur. compliant material. The hydrochloride salt form is the predominant commercial grade used in finished dosage manufacturing.

Bulk API is typically offered in kilogram to multi-kilogram quantities with full regulatory documentation support. This includes CoA, DMF references, and ICH-compliant impurity profiling for quality assurance.